Zhang Ye,Zhang Yin,Jiang Jiabin,et al.Short-term efficacy and safety of low-dose solifenacin for newly diagnosed idiopathic overactive bladder in children[J].Journal of Clinical Pediatric Surgery,2023,22(02):134-138.[doi:10.3760/cma.j.cn101785-202210053-007]
小剂量索利那新治疗儿童特发性膀胱过度活动症的短期疗效与安全性分析
- Title:
- Short-term efficacy and safety of low-dose solifenacin for newly diagnosed idiopathic overactive bladder in children
- Keywords:
- Overactive Bladder; Folifenacin; Drug Therapy; Treatment Outcome; Patient Safety; Child
- 摘要:
- 目的 探讨小剂量索利那新治疗儿童特发性膀胱过度活动症的短期疗效与安全性。 方法 回顾性分析2022年3月至2022年8月于安徽省儿童医院泌尿外科门诊就诊的27例特发性膀胱过度活动症患儿临床资料,均在行为治疗基础上加用索利那新治疗(固定剂量为每日2.5 mg)。自首诊开始随访4周,收集治疗前、服药2周后、4周后3天排尿日记及膀胱过度活动症症状评分表(OABSS),并记录患儿口干、视物模糊、便秘、恶心等不良反应。 结果 与基线相比,患儿服药2周后平均日间排尿次数从(14.7±3.8)次减少至(9.5±2.5)次(t=12.013,P<0.001,95%CI 4.33,6.12)、日间平均每次排尿量自(51.78±21.98)mL增加至(96.85±29.91)mL(t =-9.591,P<0.001,95%CI-47.45,-30.69)、尿急评分(4(3,5)分比3(3,4)分,Z=-4.025,P<0.001)、尿失禁评分(4(1,4)分比 2(0,3)分,Z=-4.373,P<0.001)、OABSS总分(9(7,12)分比7(4,8)分,Z=-4.506,P<0.001),均显著降低。服药4周后,患儿完全控尿率为48.1%,遗尿治愈率为87%,1例出现便秘,不良反应发生率为3.7%。 结论 口服小剂量索利那新(每日2.5 mg)可有效改善儿童膀胱过度活动症症状,安全性及治疗依从性好。
- Abstract:
- Objective To explore the short-term efficacy and safety of solifenacin for newly diagnosed idiopathic overactive bladder(IOAB)in children.Methods Between January and August 2022,clinical data of 3-day voiding diaries and overactive bladder symptom score(OABSS)were reviewed for 27 IOAB outpatients.Behavior therapy and 2.5 mg fixed oral daily dose solifenacin succinate were offered for 4 weeks.The efficacy and safety were evaluated at 2/4 weeks after medication.Results After 2-week medication,mean total OABSS declined markedly as compared to baseline value [9(7,12)vs.7(4,8),Z=-4.506,P<0.001].Voiding urgency [4(3,5)vs.3(3,4),Z=-4.025,P<0.001] and urgency urinary incontinence(UUI)[4(1,4)vs.2(0,3),Z=-4.373,P<0.001] significantly improved after 2-week treatment.Mean frequency during daytime decreased from(14.7±3.8)to(9.5±2.5)times(t=12.013,P<0.001,95%CI4.33,6.12)and mean voided volume spiked from(51.78±21.98)to(96.85±29.91)ml(t=-9.591,P<0.001,95%CI-47.45,-30.69)as compared to baseline data.At the end,complete continence was achieved(n=13,48.1%)and OAB symptoms improved(n=13).One patient complained of nausea,abdominal distension and constipation.No significant adverse effects were noted.Conclusion Solifenacin succinate 2.5 mg fixed dose for 2 weeks may be used for pediatric OAB.It can significantly improve the symptoms of OAB with decent safety and compliance.
参考文献/References:
[1] Akbal C, ?ahan A, ?ener TE,et al.Diagnostic value of the pediatric lower urinary tract symptom score in children with overactive bladder[J].World J Urol,2014,32(1):201-208.DOI:10.1007/s00345-013-1224-y.
[2] Franco I.Overactive bladder in children[J].Nat Rev Urol,2016,13(9):520-532.DOI:10.1038/nrurol.2016.152.
[3] 尚小平,杨静,汪玺正,等.儿童日间尿失禁流行病学调查及尿不湿的应用对其影响分析[J].中华医学杂志,2018,98(18):1434-1438.DOI:10.3760/cma.j.issn.0376-2491.2018.18.013. Shang XP,Yang J,Wang XZ,et al.Epidemiological survey and analysis of the effect of using diapers on daytime urinary incontinence in children[J].Natl Med J China,2018,98(18):1434-1438.DOI:10.3760/cma.j.issn.0376-2491.2018.18.013.
[4] 牛之彬,杨屹.生物反馈联合电刺激治疗儿童功能性排尿失调的初步研究[J].临床小儿外科杂志,2020,19(11):991-995.DOI:10.3969/j.issn.1671-6353.2020.11.006. Niu ZB,Yang Y.Biofeedback therapy plus electrical nerve stimulation for dysfunctional voiding in children[J].J Clin Ped Sur,2020,19(11):991-995.DOI:10.3969/j.issn.1671-6353.2020.11.006.
[5] Soliman MG,El-Abd S,El-Gamal OM,et al.Mirabegron versus solifenacin in children with overactive bladder:prospective randomized single-blind controlled trial[J].Urol Int,2021,105(11/12):1011-1017.DOI:10.1159/000515992.
[6] 郭立华,张谦,范应中,等.索利那新治疗小儿尿道下裂术后膀胱痉挛的疗效分析[J].中华泌尿外科杂志,2016,37(6):454-457.DOI:10.3760/cma.j.issn.1000-6702.2016.06.015. Guo LH,Zhang Q,Fan YZ,et al.Efficacy of solifenacin for bladder spasm after operations for pediatric hypospadias[J].Chin J Urol,2016,37(6):454-457.DOI:10.3760/cma.j.issn.1000-6702.2016.06.015.
[7] Peyronnet B,Mironska E,Chapple C,et al.A comprehensive review of overactive bladder pathophysiology:on the way to tailored treatment[J].Eur Urol,2019,75(6):988-1000.DOI:10.1016/j.eururo.2019.02.038.
[8] Ramsay S,Naud é,Simonyan D,et al.A randomized,crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine:the FOXY study[J].Can Urol Assoc J,2020,14(6):192-198.DOI:10.5489/cuaj.6247.
[9] Brucker BM,Lee RK,Newman DK.Optimizing nonsurgical treatments of overactive bladder in the United States[J].Urology,2020,145:52-59.DOI:10.1016/j.urology.2020.06.017.
[10] M受体拮抗剂临床应用专家共识编写组.M受体拮抗剂临床应用专家共识[J].中华泌尿外科杂志,2014,35(2):81-86.DOI:10.3760/cma.j.issn.1000-6702.2014.02.001. Expert Consensus Compiling Group on Clinical Application of M-Receptor Antagonists.Expert Consensus on Clinical Application of M-Receptor Antagonists[J].Chin J Urol,2014,35(2):81-86.DOI:10.3760/cma.j.issn.1000-6702.2014.02.001.
[11] 中华医学会小儿外科学分会小儿尿动力和盆底学组,中华医学会小儿外科学分会泌尿外科学组.儿童膀胱过度活动症诊断和治疗中国专家共识[J].中华医学杂志,2021,101(40):3278-3286.DOI:10.3760/cma.j.cn112137-20210529-01232. Group of Pediatric Urodynamics and Pelvic Floor,Society of Pediatric Surgery,Chinese Medical Association;Urology Group,Society of Pediatric Surgery,Chinese Medical Association:Chinese Expert Consensus on Diagnosing and Treating Overactive Bladder in Children[J].Natl Med J China,2021,101(40):3278-3286.DOI:10.3760/cma.j.cn112137-20210529-01232.
[12] Hoebeke P,De Pooter J,De Caestecker K,et al.Solifenacin for therapy resistant overactive bladder[J].J Urol,2009,182(4 Suppl):2040-2044.DOI:10.1016/j.juro.2009.05.100.
[13] Tannenbaum S,den Adel M,Krauwinkel W,et al.Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity[J].Pharmacol Res Perspect,2020,8(6):e00684.DOI:10.1002/prp2.684.
[14] Newgreen D,Bosman B,Hollestein-Havelaar A,et al.Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder[J].J Urol,2017,198(4):928-936.DOI:10.1016/j.juro.2017.05.038.
[15] Ghanavati PM,Khazaeli D,Amjadzadeh M.A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with solifenacin plus desmopressin,tolterodine plus desmopressin,and desmopressin alone:a randomized controlled clinical trial[J].Int Braz J Urol,2021,47(1):73-81.DOI:10.1590/S1677-5538.IBJU.2019.0448.
备注/Memo
收稿日期:2022-10-25。
基金项目:安徽医科大学校科研基金项目(2020xkj252)
通讯作者:潮敏,Email:cm0654@sina.com